News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Poll|July 16, 2015

Mini Quiz: Dietary Effects of Psychiatric Drugs

Author(s)Christina S. Won, PharmD, PhD

How do foods containing tyramine (eg, aged cheeses, fermented foods, cured meats) interact with some psychiatric medications?

The best-known pharmacodynamic interaction occurs between _______ and tyramine:

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

ByGustavo Alva, MD, DFAPA,Ann Childress, MD

June 26th 2026

Seltorexant as Adjunctive Therapy for MDD With Insomnia

Seltorexant as Adjunctive Therapy for MDD With Insomnia

ByJane Tiller, MD

June 24th 2026

pharmacogenomics

Psychiatric Pharmacogenomics: An Overview

ByAbby Ao, DO,James A. Bourgeois, OD, MD,John J. Miller, MD

June 23rd 2026

artit/Adobe Stock

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

ByJessica Walters

June 23rd 2026

Pcess609/Adobe Stock

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

ByJessica Walters

June 22nd 2026

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

Seltorexant as Adjunctive Therapy for MDD With Insomnia

Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care

Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS